Yes, we can provide some updated information to the committee on what's occurred since the Auditor General did the audits, which now are dated 2003-04, 2004-05, and 2005-06.
Two of the key areas for us have been compliance and enforcement and post-market surveillance. I should say that these are common themes for food and drug regulators around the world. If you talk to the FDA or the European Union, they will say these are the two key areas that need more investment, and we felt that's the case here as well.
I can give you some numbers just on staffing, and for us what's critical is our staff capacity. In 2004-05 we had close to 200 on staff in our inspection service. Next year we'll be up to about 260 on staff. In our post-market area in 2004-05 we had about 112 on staff, and next year we'll have 192.
We're continuing to invest additional resources into these two key areas, because we feel they are priorities for new investment, so that's what we've been doing since the years of these audits.